rs765347751
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong
The NM_000338.3(SLC12A1):c.1522G>A(p.Ala508Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000217 in 1,613,732 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000338.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC12A1 | NM_000338.3 | c.1522G>A | p.Ala508Thr | missense_variant | 12/27 | ENST00000380993.8 | NP_000329.2 | |
SLC12A1 | NM_001184832.2 | c.1522G>A | p.Ala508Thr | missense_variant | 12/27 | NP_001171761.1 | ||
SLC12A1 | NM_001384136.1 | c.1522G>A | p.Ala508Thr | missense_variant | 12/27 | NP_001371065.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC12A1 | ENST00000380993.8 | c.1522G>A | p.Ala508Thr | missense_variant | 12/27 | 5 | NM_000338.3 | ENSP00000370381.3 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152080Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000280 AC: 7AN: 250148Hom.: 0 AF XY: 0.0000296 AC XY: 4AN XY: 135178
GnomAD4 exome AF: 0.0000212 AC: 31AN: 1461652Hom.: 0 Cov.: 32 AF XY: 0.0000206 AC XY: 15AN XY: 727112
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152080Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74280
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jan 21, 2019 | The best available variant frequency is uninformative because it is below the disease allele frequency. Statistically enriched in patients compared to ethnically matched controls. Found in at least one symptomatic patient. Predicted to have a damaging effect on the protein. Results on protein functions were inconclusive. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 12, 2023 | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects SLC12A1 function (PMID: 12761241, 33973684). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SLC12A1 protein function. ClinVar contains an entry for this variant (Variation ID: 242488). This missense change has been observed in individual(s) with clinical features of Bartter syndrome type 1 (PMID: 9585600, 19096086, 20219833, 25326637, 28095294). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (rs765347751, gnomAD 0.005%). This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 508 of the SLC12A1 protein (p.Ala508Thr). - |
Bartter disease type 1 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 29, 2018 | The SLC12A1 c.1522G>A (p.Ala508Thr) variant has been reported in three studies and in a total of four unrelated patients with Bartter syndrome, including one in a homozygous state, two in a compound heterozygous state, and one in a heterozygous state in whom a second variant was not detected (Vargas-Poussou et al. 1998; Puricelli et al. 2010; Wongsaengsak et al. 2017). The p.Ala508Thr variant was absent from 100 controls (Vargas-Poussou et al. 1998; Puricelli et al. 2010) and is reported at a frequency of 0.00009 in the European (non-Finnish) population of the Exome Aggregation Consortium. Functional testing demonstrated that the p.Ala508Thr variant resulted in a protein with reduced sodium uptake activity (Starremans et al. 2003). Based on the evidence, the p.Ala508Thr variant is classified as likely pathogenic for antenatal Bartter syndrome. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at